The Intravenous Immunoglobulin Market continues to grow at a remarkable pace, with its valuation at USD 14.02 billion in 2024 and projected to reach USD 25.39 billion by 2032. This growth trajectory represents a compound annual growth rate (CAGR) of 7.72% between 2025 and 2032. The market’s expansion is closely tied to increasing cases of autoimmune and neurological disorders, broader applications of IVIG in off-label therapies, and the global surge in demand for life-saving plasma-derived products.

Growing Need for Immunoglobulin Therapies
Intravenous immunoglobulin (IVIG) has become a cornerstone therapy in treating a wide array of conditions, from primary and secondary immunodeficiency to autoimmune and neurological disorders. The growing prevalence of conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, Guillain-Barré syndrome, and immune thrombocytopenia is significantly driving demand.

Beyond these, IVIG has gained traction in off-label applications, including its role in treating severe infections and complications from organ transplants. With patients worldwide seeking reliable immune-boosting therapies, manufacturers are scaling up production and investing in advanced purification technologies to ensure safety and effectiveness.

Read More: https://www.snsinsider.com/reports/intravenous-immunoglobulin-market-7356